Vote Scores
Filings read through

Shanghai Pharmaceuticals Holding Co., Ltd.: how funds voted at the meeting of 28 Jun 2024

Meeting
Season
year to 30 June 2024
Filers reporting
58
Ballot items
7

58 filers on Form N-PX reported votes at the Shanghai Pharmaceuticals Holding Co., Ltd. meeting of 28 Jun 2024. The records fall into 7 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Shanghai Pharmaceuticals Holding Co., Ltd. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    1 nominee. 91.3% of the reported votes are for. 2 filers withheld from or voted against at least one nominee.

    23 vote records from 15 filers. 3 of the 15 filers that marked the item voted against management.

    • Positions of 8 fund families
    • For 7
    • Against 1
    • Against management 2
  2. Item 2: Director elections (nominees put forward by security holders)

    1 nominee. 99.2% of the reported votes are for. 1 filer withheld from or voted against at least one nominee.

    130 vote records from 43 filers. 1 of the 43 filers that marked the item voted against management.

    • Positions of 18 fund families
    • For 17
    • Against 1
    • Against management 1
  3. Item 3: Audit-related items (auditor ratification)

    158 vote records from 58 filers. 1 of the 58 filers that marked the item voted against management.

    • Positions of 25 fund families
    • For 25
    • Against management 1
  4. Item 4: EXTRAORDINARY TRANSACTIONS: management items

    The company's items in this category are shown together, because filers word and number them differently.

    21 vote records from 13 filers. 7 of the 13 filers that marked the item voted against management.

    • Positions of 7 fund families
    • For 3
    • Against 4
    • Against management 4
  5. Item 5: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    3,011 vote records from 58 filers. 6 of the 58 filers that marked the item voted against management.

    • Positions of 25 fund families
    • For 22
    • Against 3
    • Against management 3
  6. Item 6: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    706 vote records from 51 filers. 1 of the 51 filers that marked the item voted against management.

    • Positions of 22 fund families
    • For 22
    • Against management 1
  7. Item 7: OTHER: management items

    The company's items in this category are shown together, because filers word and number them differently.

    105 vote records from 9 filers. 0 of the 9 filers that marked the item voted against management.

    • Positions of 3 fund families
    • For 3

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Shanghai Pharmaceuticals Holding Co., Ltd., meeting of 28 Jun 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family3. Auditor
American CenturyFor
BlackRock and iSharesFor
BNY MellonFor
Brighthouse FundsFor
Charles SchwabFor
DimensionalFor
EquitableFor
FidelityFor
Franklin TempletonFor
Hartford FundsFor
InvescoFor
J.P. MorganFor
Jackson National fundsFor
John Hancock and ManulifeFor
Lincoln FinancialFor
Morgan Stanley, Eaton Vance and CalvertFor
Neuberger BermanFor, against management
Northern Trust and FlexSharesFor
Nuveen and TIAAFor
Pacific Life fundsFor
SEIFor
State Street and SPDRFor
VanguardFor
VoyaFor
WisdomTreeFor

Questions

How many filers reported votes at the Shanghai Pharmaceuticals Holding Co., Ltd. meeting?
58 Form N-PX filers reported votes at the meeting of 28 Jun 2024.
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Shanghai Pharmaceuticals Holding Co., Ltd. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Shanghai Pharmaceuticals Holding Co., Ltd. with a meeting date within three days of 28 Jun 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .